{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:30:49Z","timestamp":1786595449765,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disorder, yet effective disease-modifying therapies remain elusive. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used in the management of type 2 diabetes mellitus (T2DM), have shown neuroprotective potential in preclinical studies. However, real-world evidence on the association between GLP-1RAs use and PD risk remains inconsistent and has not been systematically synthesized. This systematic review and meta-analysis aimed to evaluate this association using large-scale real-world data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from database inception to March 18, 2026, for cohort and case\u2013control studies exploring the association between GLP-1RA exposure and PD risk among patients with T2DM. Study selection, data extraction, and methodological quality assessment were independently conducted by two reviewers. All meta-analyses were performed using Stata 15.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of six studies were included, involving 452,763 participants. The meta-analysis revealed that GLP-1RA exposure was significantly associated with a reduced risk of PD in patients with T2DM (HR\u00a0=\u00a00.68, 95%CI (0.54,0.85), P\u00a0=\u00a00.001). Subgroup analyses demonstrated that compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, metformin, and other hypoglycemic drugs, GLP-1RAs were linked to a lower risk of incident PD (DPP-4 inhibitors: HR\u00a0=\u00a00.60, 95%CI (0.43,0.83), P\u00a0=\u00a00.001; Metformin: HR\u00a0=\u00a00.83, 95%CI (0.73,0.95), P\u00a0=\u00a00.006; Other: HR\u00a0=\u00a00.73, 95%CI (0.60,0.87), P\u00a0=\u00a00.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This meta-analysis based on large-scale real-world data indicates that GLP-1RA exposure is associated with a lower risk of PD in patients with T2DM, with robust and consistent results across diverse comparator groups. These findings support the hypothesis that GLP-1RAs may confer neuroprotective properties, a finding that merits further rigorous investigation. Nevertheless, given the inherent limitations inherent to observational study designs and the possibility of residual confounding in the included studies, the present results should be regarded as preliminary and hypothesis-generating rather than conclusive. Future large-scale prospective cohort studies with standardized methodologies, as well as well-designed randomized controlled trials, are warranted to validate these findings and clarify whether the observed inverse association reflects a causal neuroprotective effect of GLP-1RAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1849318","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:24:41Z","timestamp":1786595081000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists and the risk of Parkinson\u2019s disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data"],"prefix":"10.3389","volume":"17","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiping","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/acem.70269","article-title":"An underrecognized problem: Missed and delayed carbidopa-levodopa administration in emergency department patients with Parkinson's disease","volume":"33","author":"Elder","year":"2026","journal-title":"Acad Emergency Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27062560","article-title":"Repurposing antidiabetic medications for Parkinson's disease: Focus on biomarker strategies for disease modification","volume":"27","author":"Yelleswarapu","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afag063","article-title":"Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease","volume":"55","author":"Pourzinal","year":"2026","journal-title":"Age Ageing"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint18030045","article-title":"Potential effects of music on non-motor symptoms in Parkinson's disease: Translating mechanisms to therapy","volume":"18","author":"Ballmann","year":"2026","journal-title":"Neurol Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cells15010042","article-title":"Non-motor symptoms: The hidden face of Parkinson's disease","volume":"15","author":"Cattaneo","year":"2025","journal-title":"Cells"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/14737167.2024.2390042","article-title":"Burden of non-motor symptoms of Parkinson's disease: Cost-of-illness and quality-of-life estimates through a scoping review","volume":"25","author":"van der Meer","year":"2025","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22643","article-title":"The Priamo study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease","volume":"24","author":"Barone","year":"2009","journal-title":"Movement Disorders: Off J Movement Disord Soc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","article-title":"Economic burden of Parkinson's disease: A multinational, real-world, cost-of-illness study","volume":"11","author":"Chaudhuri","year":"2024","journal-title":"Drugs - Real World Outcomes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000003549","article-title":"Risk of Parkinson disease in diabetes mellitus: An updated meta-analysis of population-based cohort studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s580095","article-title":"Cardiovascular outcomes and safety of GLP-1 receptor agonists in elderly patients with type 2 diabetes: A systematic review and meta-analysis","volume":"19","author":"Gao","year":"2026","journal-title":"Diabetes Metab Syndrome Obesity: Targets Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1729904","article-title":"Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2","volume":"12","author":"Shao","year":"2025","journal-title":"Front Mol Biosci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/25424823251342182","article-title":"Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review","volume":"9","author":"Chuansangeam","year":"2025","journal-title":"J Alzheimer's Dis Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100133","article-title":"The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson's disease: A systematic review and meta-analysis","volume":"6","author":"Dahiya","year":"2022","journal-title":"Clin Parkinsonism Related Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson's disease: A cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70075","article-title":"GLP-1 agonists as potential neuromodulators in development of Parkinson's disease: A nationwide cohort study","volume":"32","author":"Gamborg","year":"2025","journal-title":"Eur J Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107132","article-title":"Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study","volume":"128","author":"Rozani","year":"2024","journal-title":"Parkinsonism Related Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70459","article-title":"GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes","volume":"28","author":"Sun","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5448","article-title":"Association between different diabetes medication classes and risk of Parkinson's disease in people with diabetes","volume":"31","author":"Sunnarborg","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29992","article-title":"Glucagon-like peptide-1 receptor agonists and risk of Parkinson's disease in patients with type 2 diabetes: A population-based cohort study","volume":"39","author":"Tang","year":"2024","journal-title":"Movement Disorders: Off J Movement Disord Soc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/HM9.0000000000000172","article-title":"Effectiveness of acupuncture in managing aromatase inhibitor-related arthralgia in breast cancer: A systematic review and meta-analysis","volume":"5","author":"Zhu","year":"2025","journal-title":"Acupuncture Herbal Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/hm9.0000000000000093","article-title":"Efficacy and safety of acupuncture in treating low back and pelvic girdle pain during pregnancy: A systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Zhang","year":"2024","journal-title":"Acupuncture Herbal Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251408269","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson's disease: A systematic review and meta-analysis of randomized placebo-controlled clinical trials","volume":"19","author":"Stefanou","year":"2026","journal-title":"Ther Adv Neurological Disord"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.71344","article-title":"Efficacy and safety of glucagon-like peptide 1 receptor agonists in Parkinson disease: A systematic review and meta-analysis","volume":"16","author":"Raza","year":"2026","journal-title":"Brain Behav"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1900\/rds.2009.6.247","article-title":"Preclinical and clinical data on extraglycemic effects of GLP-1 receptor agonists","volume":"6","author":"Gallwitz","year":"2009","journal-title":"Rev Diabetic Studies: RDS"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.141319","article-title":"Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions","volume":"18","author":"Singh","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08370-w","article-title":"Metformin as a potential neuroprotective agent that influence Parkinson's disease","volume":"46","author":"Pal","year":"2025","journal-title":"Neurological Sciences: Off J Ital Neurological Soc Ital Soc Clin Neurophysiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110743","article-title":"GLP-1 and the degenerating brain: Exploring mechanistic insights and therapeutic potential","volume":"26","author":"Moaket","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13205-021-02738-3","article-title":"Role of insulin receptor substance-1 modulating PI3K\/Akt insulin signaling pathway in Alzheimer's disease","volume":"11","author":"Zheng","year":"2021","journal-title":"3 Biotech"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163288","article-title":"GLP-1 RAs and SGLT2i: Two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway","volume":"14","author":"Mazzieri","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: A focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front Neurosci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1849318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:24:42Z","timestamp":1786595082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1849318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1849318"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1849318","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1849318"}}